key: cord-0996591-jn202ojm
authors: Kruse, Margaret; Dark, Chris; Aspden, Megan; Cochrane, Daniel; Competiello, Rick; Peltz, Maya; Torres, Luis; Wrighton-Smith, Peter; Dudek, Magdalena
title: Performance of the T-SPOT®.COVID test for detecting SARS-CoV-2-responsive T cells
date: 2021-09-30
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.09.073
sha: 46851313d1acb8db894aa01417a1bd93c101796b
doc_id: 996591
cord_uid: jn202ojm

Objective This study evaluated the performance of the T-SPOT.COVID test for identifying SARS-CoV-2-responsive T-cells in subjects with SARS-CoV-2 infections. Methods The T-SPOT.COVID test uses ELISpot interferon-gamma release assay (IGRA) methodology to measure T cell responses to SARS-CoV-2 spike S1 and nucleocapsid peptides. T-SPOT.COVID and anti-N IgG serology tests were performed on blood from 186 subjects with NAAT-confirmed-SARS-CoV-2 infections and 100 control subjects. Results In the 2-8 week-period after NAAT-diagnosed SARS-CoV-2 infection, the T-SPOT.COVID test detected 98.4% (63/64) of infected subjects; in comparison, anti-N IgG serology detected fewer in this time period (82.8%, 53/64). In the first 2 weeks after diagnosis, during activation of the adaptive immune response, there were fewer reactive T-SPOT.COVID responses (75.7%, 28/37) and many fewer seropositive responses (32.4%, 12/37). Response numbers tapered somewhat after 8 weeks, although T-SPOT.COVID test continued to detect most of the confirmed-infection subjects (83.6%, 56/67) and continued to out-perform serology (52.2%, 35/67). The possibility of T-SPOT.COVID responses due to cross-reactive T cells was ruled out by demonstrating that, of 44 control subjects with T cells responsive to four human common cold coronavirus peptides, only 1 was T-SPOT.COVID reactive. Conclusion The T-SPOT.COVID test performed well in detecting SARS-CoV-2-sensitized T-cells over many months.

Long-term protection from infections such as the SARS-CoV-2 virus is mediated by T cells and antibody-mediated immunity of the adaptive immune system (Sette and Crotty, 2021) . The T-SPOT®.COVID test was developed to identify the presence of SARS-CoV-2-responsive T cells.

T cells contribute to the understanding of SARS-CoV-2 infections in many ways. T cells can identify past SARS-CoV-2 infections at a time when PCR tests would be negative and antibodies levels may be waning Gudbjartsson et al., 2020; Poland et al., 2020) . T cells can provide immune memory lasting for months and perhaps years, as suggested by the finding of T cells to the SARS-CoV-1 coronavirus 17 years after infection (Le Bert et al., 2020) . T cells may act independently of antibodies to control a SARS-CoV-2 infection as shown by the recovery of COVID-19 patients who lack detectable antibodies but have SARS-CoV-2-responsive T cells (Gallais et al., 2021; Sekine et al., 2020) . T cells also show reactivity to numerous SARS-CoV-2 epitopes and so have potential to protect against many SARS-CoV-2 variants Tarke et al., 2021) . T cell-based assays can probe the longevity of an immune response following a SARS-CoV-2 infection or vaccination (Goletti et al., 2021; Liu et al., 2021; Reynolds et al., 2021) . These various roles suggest that a T cell assay can be a key contributor to SARS-CoV-2 investigations.

The T-SPOT.COVID test, an enzyme-linked immunospot (ELISpot) assay, identifies T cells in peripheral blood that release interferon gamma (IFN-) in response to stimulation with SARS-CoV-2 peptides. The T-SPOT.COVID test builds on the T-SPOT® platform (Oxford Immunotec) that is used worldwide for tuberculosis and CMV testing as well as the research version, the T-SPOT® Discovery SARS-CoV-2 test (Liu et al., 2021; Wyllie et al., 2021) . The T-SPOT.COVID ELISpot methodology is performed in many laboratories and offers a standardized comparison of T cell immunity among subjects. In addition, ELISpot assays normalize the number of PBMCs, thus maintaining test effectiveness in subjects with lymphopenia, a commonly reported condition in many COVID-19 patients (Altmann and Boyton, 2020) , as well as in immunosuppressed people.

The objective of this study was to evaluate the ability of the T-SPOT.COVID test to detect T cell responses in subjects with or without a history of SARS-CoV-2 infections and to compare the T-SPOT.COVID test results to anti-N IgG serology results in the first several months after infection.

Subjects for this single center, cross-sectional study were recruited from among those who had attended the outpatient Primacare medical center in Fall River, Massachusetts, USA, between November 30, 2020, and March 24, 2021, a time of high demand for COVID-19 testing. Among other healthcare services, Primacare provided COVID-19 testing that was available to anyone wanting or required to be tested. New England Center for Clinical Research (NECCR) invited participants to join the study if they had received a positive SARS-CoV-2 nucleic acid amplification test (NAAT) at Primacare or if they were deemed by NECCR to be at low risk of SARS-CoV-2 infection. As this study was run independently from the subjects' healthcare providers, clinical data such as chest x-rays and hospitalizations records were not obtained.

Informed consent and study approval were obtained from Advarra IRB by NECCR at Primacare.

Confirmed-infection subjects: Nucleic acid amplification tests (NAAT) detect the presence of the SARS-CoV-2 virus and were used to identify people infected with SARS-CoV-2 at the time of testing (Rai et al., 2021) . Subjects in the confirmed-infection cohort were recruited from asymptomatic and symptomatic patients who had a positive SARS-CoV-2 NAAT result within the past 9 months. The date of the first positive NAAT result was considered the date of diagnosis of SARS-CoV-2 infection. Blood was drawn for Abbott SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) anti-N IgG serology and T-SPOT.COVID tests between 0 to 249 days after diagnosis.

The analysis of responses was divided into three time periods: 0 to 2 weeks after diagnosis (0 to 14 days), 2+ to 8 weeks after diagnosis (15 to 56 days), and 8+ weeks after diagnosis (57+ days).

Control subjects: Many SARS-CoV-2 studies use frozen pre-pandemic blood for control samples; however, the T-SPOT platform requires fresh blood to ensure consistency of results, and therefore fresh blood was obtained from control subjects who were prospectively recruited from individuals with a low risk of a prior SARS-CoV-2 infection. Requirements for enrollment included no current or prior signs or symptoms of COVID-19 disease, no known contact with a confirmed SARS-CoV-2-infected individual, no prior history of a positive SARS-CoV-2 NAAT, no SARS-CoV-2 vaccination, and no prior diagnosis with SARS-CoV-1 or MERS. In addition, the BIOHIT HealthCare SARS-CoV-2 lateral flow anti-N IgM/IgG serology test was performed at enrollment, and the one person with a positive BIOHIT result was not enrolled. Blood was drawn at enrollment for testing with T-SPOT.COVID and the Abbott CMIA anti-N IgG serology test, and anyone with a positive serology result was subsequently excluded from the control group.

The T-SPOT.COVID test includes over 250 SARS-CoV-2 peptides (15-mer peptides overlapping by 11 amino acids) in two antigen peptide pools; one pool containing peptides from the spike S1 protein including the receptor binding domain and the other pool containing peptides from the nucleocapsid protein.

Blood samples for the T-SPOT.COVID test were processed and analyzed according to the manufacturer's instructions. Briefly, blood samples were drawn into lithium heparin tubes which were shipped overnight to Oxford Immunotec, Abingdon, UK, in temperature-controlled shipping boxes. Next, the T-Cell Xtend® reagent (Oxford Immunotec) was added to the samples, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation, washed, counted, and 250,000 cells/well were plated into four wells of a 96-well plate.

The two antigen peptide pools were added to the two antigen wells, the T cell mitogen phytohemagglutinin to the positive control well, and cell culture media alone to the negative control well. After 16-20 hours incubation, the wells were washed and developed using a conjugated secondary antibody that bound to any IFN- captured on the membrane. After washing to remove unbound IFN-, substrate was added to produce dark spots of insoluble precipitate indicating areas of IFN- secretion from T cells. These spot forming cells (SFCs) were counted using an automated ELISpot plate reader (CTL, Shaker Heights, OH) and manually verified. Results were 'invalid' if the negative control had more than 10 SFCs or the positive control had fewer than 20 SFCs when the antigen wells were non-reactive. The cutoff of the test was pre-determined at 6 SFCs using a ROC curve derived from confirmed-infection and low 8 risk samples from another cohort (data not shown), as that cut off gave the optimal sensitivity and specificity for the test. A borderline zone of +/-1 SFCs was introduced to account for potentially elevated test variability around the cutoff (Rego et al., 2018) . Consequently, results were 'reactive' when the SFCs in the higher of the two antigen wells minus the negative control were ≥ 8, 'non-reactive' when the SFCs in both antigen wells minus the negative control were ≤ 4, and 'borderline' when the SFCs in the higher of the antigen wells minus the negative control were 5, 6, or 7. The SFC results presented below refer to counts from the higher of the two antigen wells.

Due to homology between virus sequences, common cold human coronavirus (HCoV) endemic strains can generate T cells capable of cross-reacting with some SARS-CoV-2 peptides (Braun et al., 2020; Mateus et al., 2020) . To minimize the chance of T-SPOT.COVID responses being elicited by cross-reactive T cells in the absence of a SARS-CoV-2 infection, the T-SPOT.COVID test omits peptides from the S2 region of the SARS-CoV-2 spike protein, as the majority of SARS-CoV-2 / HCoV homologous sequences are in this region (Braun et al., 2020) . In addition, a sequencing search tool and genetic sequence database were used to identify sequences in the spike, nucleocapsid, membrane, and envelope proteins with high amino acid homology between SARS-CoV-2 and the HCoVs; any spike S1 and nucleocapsid high homology sequences identified in this way were also omitted from the T-SPOT.COVID test.

To explore potential cross-reactive T cell responses, five 'cross-reactivity' peptide pools were manufactured, consisting of a 'high homology' pool containing the identified highly homologous peptides and four 'HCoV pools' containing spike peptides from four HCoVs (HKU1, 229E, NL63, 9 and OC43). For the cross-reactivity analysis, after subtracting the negative control SFCs, the T-SPOT.COVID cutoff of ≥ 6 SFCs defined a reactive response and < 5 SFCs defined a nonreactive response.

Receiver operating characteristic (ROC) curve analysis by GraphPad Prism 9.1.1 for Windows was used to evaluate the SFC separation between reactive and non-reactive T-SPOT.COVID results. Other statistical analyses were performed using SAS version 9.4, SAS Institute, Cary NC, USA. The maximum SFC counts for the control and confirmed-infection groups were compared using Pearson's test with Yate's correction. Control subject responses to each of the five crossreactivity peptide pools were compared to their T-SPOT.COVID response using the McNemar test. A p-value of < 0.05 was considered significant.

Of 204 subjects initially screened for the confirmed-infection cohort, 17 were excluded because results for the anti-N IgG serology test were not available and one was excluded due to an insufficient number of PBMCs to perform the T-SPOT.COVID test. The remaining 186 confirmedinfection subjects, 114 females and 72 males, ranged from 19 to 83 years old (Table 1 ). The majority of these subjects (176/186, 94.6%) had symptomatic COVID-19 (Table 1) , with the remainder having NAAT-confirmed asymptomatic SARS-CoV-2 infections.

Of the 112 subjects initially screened as controls, 12 were excluded: 6 due to positive anti-N IgG serology results, 4 due to unavailable anti-N serology results, 1 due to insufficient number of PBMCs, and 1 due to technical error in test performance. The remaining 100 controls, 64 females and 36 males, ranged from 18 to 87 years old (Table 1) .

The peptides included in the T-SPOT.COVID test were selected to minimize the chance for crossreactivity from T cells sensitized by a prior HCoV infection. The success of this strategy was evaluated by testing the control subject responses to the five cross-reactivity pools (four HCoV peptide pools and the high homology peptide pool).

The majority of control subjects (56/100, 56.0%) did not respond to any of the five crossreactivity pools while 44/100 (44%) had responses ( Figure 1 ). Not all of these 44 controls responded to each cross-reactivity pool: The HKU1 pool elicited responses from 18%, 229E from 34%, NL63 from 29%, OC43 from 26%, and the high homology pool from 6%.

Of the 44 control subjects who responded to the cross-reactivity peptides, only 1 responded to the T-SPOT.COVID peptides, while 98% (43/44) subjects with proven HCoV-responsive T cells did not show T-SPOT.COVID reactivity.

The above results show that HCoV-responsive T cells did not lead to reactive T-SPOT.COVID results. The converse, that reactive T-SPOT.COVID results did not necessarily signify HCoVresponsiveness, was also observed: Of the 3 control subjects with T-SPOT.COVID results ≥ 6

SFCs (1 borderline, 2 reactive), 2 subjects were HCoV-non-responsive and 1 subject was HCoVresponsive.

A ROC curve analysis was conducted using the 186 confirmed-infection and 100 control subjects which confirmed the appropriateness of the pre-determined 6 SFC cutoff and yielded an area under the curve of 0.95 (95% CI: 0.92 to 0.98) (Figure 2A) .

No invalid T-SPOT.COVID results occurred in either the confirmed-infection or control groups.

Borderline results were seen in 18 (9.7%) of the 186 confirmed-infection subjects and 2 (2%) of the 100 control subjects. The borderline rates in the confirmed-infection subjects may have been influenced by the timing of the test (see Discussion). As borderline results are neither reactive nor non-reactive, subjects with borderline results were not included in the following analysis which focused on reactive and non-reactive T-SPOT.COVID results.

A total of 98 control subjects had T-SPOT.COVID reactive and non-reactive results; of these, 98.0% (96/98) had non-reactive T-SPOT.COVID results and, as predetermined by the inclusion criteria, 100% (98/98) were anti-N IgG seronegative.

A total of 168 confirmed-infection subjects had T-SPOT.COVID reactive and non-reactive results.

In the 2+ to 8 weeks after diagnosis , 98.4% (63/64) of confirmed-infection subjects had reactive T-SPOT.COVID results and 82.8% (53/64) were anti-N IgG seropositive.

The SFC count ranged from 0 to 234 (median 29) in the confirmed-infection subjects and from 0 to 4 (median 1) in the 96 control subjects with non-reactive results ( Figure 2B ). In the 2 control subjects with reactive T-SPOT.COVID results, one had 24 SFCs and the other 140 SFCs, counts near or well above the median for the confirmed-infection subjects.

Within the first two weeks after diagnosis, 75.7% ( results. Subdividing this latter period into three periods of 8+ to 14 weeks, 14+ to 20 weeks, and 20+ to 36 weeks, T-SPOT.COVID reactivity was 86.1%, 91.7%, and 73.7%, respectively, and anti-N IgG serology was 86.1%, 33.3%, and 0%, respectively ( Figure 3A ).

Reactive T-SPOT.COVID results were observed in 6 of the 9 asymptomatic subjects: 1 of 3 tested in the first two weeks, 4 of 4 between 2+ to 8 weeks, and 1 of 2 after 8 weeks. The serology tests were positive in 4 of the 9 asymptomatic subjects: 1 of 3 tested in the first two weeks, 3 of 4 between 2+ to 8 weeks, and 0 of 2 after 8 weeks.

Among the 168 confirmed-infection subjects, 152 (90.5%) were detected by the T-SPOT.COVID test and/or the serology test across all time points. Overall, 95 confirmed-infection subjects were detected by both tests, while the T-SPOT.COVID test detected an additional 52 subjects not detected by serology, and serology detected 5 subjects not detected by the T-SPOT.COVID test ( Figure 3B ).

The 16 confirmed-infection subjects not detected by either test were all tested either during the first two weeks following diagnosis (n=9) or more than 8 weeks after diagnosis (n=7).

The T-SPOT.COVID test was highly accurate at differentiating confirmed-infection and control subjects as shown by the area under the ROC curve of 0.95.

Responses to the cross-reactivity peptide pools were observed in 44% of the control subjects, agreeing with reports that 35-50% of control blood obtained during the SARS-CoV-2 pandemic had cross-reactive T cells (Braun et al., 2020; Le Bert et al., 2020) . That 43 of 44 control subjects had HCoV-responsive T cells but non-reactive T-SPOT.COVID results demonstrates that the T-SPOT.COVID test did not induce cross-reactive responses from these subjects' T cells. These findings confirm that reactive T-SPOT.COVID results observed in confirmed-infection subjects were generated by T cells activated by the SARS-CoV-2 virus.

The low number of control subjects (n=6) responding to the high homology pool is of interest when compared to the greater number (n=44) responding to the HCoV pools. The high homology sequences, by definition, were contained in the HCoVs that infected these 44 subjects, so that 86.4% (38/44) of these subjects did not show immune responses to the high homology peptides indicates that the high homology peptides were not highly immunogenic. This is understandable from an evolutionary viewpoint: An immune response to a viral peptide creates an evolutionary pressure to mutate that peptide; the more immunogenic the peptide, the higher the pressure to mutate. Conversely, we suggest that a lack of evolutionary pressure in non-immunogenic regions would result in fewer mutations and, therefore, higher homology across coronaviruses. Thus, low immunogenicity resulting in high homology can explain the low level of immune response to the high homology peptides reported here.

14 The observation of reactive T-SPOT.COVID results in 6 of 9 asymptomatic, NAAT-confirmedinfection subjects demonstrate that T cells may be present in asymptomatic subjects in the absence of antibodies, as reported elsewhere (Gallais et al., 2021; Schulien et al., 2020; Sekine et al., 2020) . Therefore, our finding of 2 control subjects with T-SPOT.COVID reactivity may be attributable to undetected asymptomatic SARS-CoV-2 infections. Supporting this, these subjects' T-SPOT.COVID SFC counts of 24 and 140 were well above the 8 SFCs required for a reactive result, thus suggesting a true T cell response. The lack of response from one of these subjects to the five cross-reactivity pools indicates that this individual's T-SPOT.COVID reactivity was not due to cross-reactive T cells. The other individual had responses to two of the five crossreactivity pools, but these were lower in magnitude than the response to the T-SPOT.COVID test, consistent with a recent SARS-CoV-2 infection and prior HCoV infections. In sum, these 2 control subjects with reactive T-SPOT.COVID results may have had undetected, asymptomatic

This study also showed that timing with respect to infection must be considered when interpreting immunological test results. The analysis of responses was divided into three time periods: 0 to 2 weeks after diagnosis, a period when the innate immune system activates the adaptive immune response (Koblischke et al., 2020; Sette and Crotty, 2021) ; 2+ to 8 weeks after diagnosis, when adaptive immune responses are commonly observed (Cohen et al., 2021; Tan et al., 2021) ; and 8+ weeks after diagnosis, when adaptive immune responses begin to taper off in some people (Cohen et al., 2021; Dan et al., 2021; Tan et al., 2021) .

The percentage of T-SPOT.COVID reactive results in the confirmed-infection group was lowest, 75.7%, within the first two weeks after diagnosis, as would be expected due to a 6-10+ day delay in the appearance of T cells following a SARS-CoV-2 infection (Koblischke et al., 2020; Sette and Crotty, 2021) . This suggests that repeated testing could be appropriate in cases of a non-reactive T-SPOT.COVID result shortly after suspected SARS-CoV-2 exposure.

In the 2+ to 8 weeks following diagnosis, virtually all confirmed-infection subjects (98.4%)

showed T-SPOT.COVID reactive responses indicating both the successful activation of SARS-

More than eight weeks after diagnosis, the percentage of subjects with T cell responses was a little lower (83.6%), in keeping with prior reports of a reduction in T cells in some subjects over time. For example, migrant dormitory residents with SARS-CoV-2 infections showed a decline in SARS-CoV-2-responsive T cells over 3 months (asymptomatic) or 7 months (symptomatic) after infection (Le . Another study reported CD4+ and CD8+ T cell responses in the blood of 70% and 93%, respectively, of COVID-19 subjects at an average of 1 month post symptom onset, which fell to 50% and 92% of subjects by 6+ months post symptom onset . A longitudinal study of individual subjects reported detectable SARS-CoV-2-specific T cells when measured at 10 days post symptom onset, which decreased in numbers for up to 14 weeks (Schulien et al., 2020) .

Taken together, these results show that most SARS-CoV-2-infected subjects generate and retain T-SPOT.COVID-detectable T cells for several months after infection.

Changing T cell responses following a SARS-CoV-2 infection may explain the large percentage of borderline results observed in confirmed-infection subjects: borderline results could be due to the timing of the T-SPOT.COVID test in relationship to developing T cell responses following infection or to the falling off of T cell responses in some subjects over time.

Serology showed a similar pattern of rise and fall with time, although the detection rate was lower at all time points. Overall, the T-SPOT.COVID test detected more confirmed-infection subjects (147/168) than did the anti-N IgG serology test (100/168) ( Figure 3B ), a difference that was especially marked within the first two weeks after infection (75.7% vs. 32.4%, respectively).

The low level of serology responsiveness in these first two weeks is in keeping with the reported two or more weeks required to develop an antibody response (Bond et al., 2020; Tan et al., 2020 Tan et al., , 2021 , which is attributable to the need for T helper cell activation prior to antibody production and to a further delayed appearance of IgG antibodies.

In subjects tested more than eight weeks after infection, the T-SPOT.COVID test detected more confirmed-infection subjects than serology (83.6% and 52.2%, respectively). By 20 to 36 weeks post diagnosis, T cells were detected in approximately three-quarters of the confirmedinfection subjects while anti-N IgG responses were not observed in any subjects. An earlier waning of anti-SARS-CoV-2 antibodies compared to T cells, particularly anti-N antibodies, has been reported (Cohen et al., 2021; Dan et al., 2021; Schulien et al., 2020) , but does not mean an ineffectual humoral response to future infections; SARS-CoV-2-responsive B cells have been detected as antibodies wane Turner et al., 2021) providing a mechanism for future antibody production.

Limitations of this study include the inability to be certain that the control subjects had never been exposed to the SARS-CoV-2 virus given the endemic nature of the virus, the potential for asymptomatic infections, and the potential for false negative test results. Also, subjects were enrolled from only one location and so these findings should be confirmed in a wider population; however, the T-SPOT.COVID test's hundreds of peptides could enable the test to work for most HLA types found worldwide. The possibility of cross-reactivity due to SARS-CoV-1 or MERS in some subjects cannot be excluded; however, this possibility is low because a history of SARS-CoV-1 or MERS infections were exclusion criteria and also because only 27 SARS-CoV-1 and 2 MERS cases were reported in the US (CDC, 2019; WHO, 2015) . In addition, no sequencing was done to determine whether any subjects were infected with SARS-CoV-2 variants; however, the hundreds of SARS-CoV-2 peptides included in the T-SPOT.COVID test may maintain performance against SARS-CoV-2 variants, and, furthermore, most known mutations have occurred in the S1 spike protein (Shah et al., 2021) and so the T-SPOT.COVID nucleocapsid peptide pool could help maintain T-SPOT.COVID performance with SARS-CoV-2 variants.

In conclusion, this study demonstrated that the T-SPOT.COVID test effectively identified asymptomatic and symptomatic individuals with SARS-CoV-2-responsive T cells beginning shortly after an infection and continuing for several months after infection. The T-SPOT.COVID test identified many confirmed-infection subjects not identified by anti-N IgG serology, indicating that testing for T cells as well as antibodies can provide a more complete picture of a patient's immune response. The clinical and public health implications of a long-lasting SARS- weeks post diagnosis, due to the timing of subject recruitment and lulls in regional COVID-19

cases and PCR testing. 

Conflict of Interest: LT reports no conflict-of-interest. The remaining authors are employees of Oxford Immunotec, Ltd. Funding Source: The study sponsor was Oxford Immunotec, Ltd., UK. Ethical Approval: Informed consent and study approval were obtained from Advarra IRB by

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

Evaluation of

Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion

The potential clinical utility of measuring SARS-CoV-2-specific T-cell responses

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Humoral Immune Response to SARS-CoV-2 in Iceland

Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity

Highly functional virusspecific cellular immune response in asymptomatic SARS-CoV-2 infection

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Karunasagar Iddya. Detection technologies and recent developments in the diagnosis of COVID-19 infection

Utility of the T-SPOT ® . TB test's borderline category to increase test resolution for results around the cut-off point

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Characterization of preexisting and induced SARS-CoV-2-specific CD8+ T cells

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Adaptive immunity to SARS-CoV-2 and COVID-19

The Case for S2: The Potential Benefits of the S2

Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic

The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

WHO. Summary of probable SARS cases with onset of illness from 1

responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkers